Pharmaceutical formulations having improved disintegration and/or absorptivity

• US 5,948,438 A
• Filed: 06/04/1997
• Issued: 09/07/1999
• Est. Priority Date: 01/09/1995
• Status: Expired due to Fees

• Current Assignee: J Rettenmaier & Sohne GmbH Company KG
• Original Assignee: Edward Mendell Co., Inc.
• Inventors: Hunter, Edward A., Staniforth, John N., Sherwood, Bob E.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Benston, Jr., William E.
• Application Number:
  US08/868,744
• Time in Patent Office: 825 Days
• Field of Search: 424/489, 424/464, 424/488, 424/490, 424/486, 424/487
• US Class Current: 424/464
• CPC Class Codes: A61K 9/2009 Inorganic compounds
• CPC Class Codes: A61K 9/2013 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/2018 Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
• CPC Class Codes: A61K 9/2036 Silicones; Polysiloxanes
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: Y10S 977/801 Drug
• CPC Class Codes: Y10S 977/906 Drug delivery
• CPC Class Codes: Y10S 977/915 Therapeutic or pharmaceutical composition

Abstract

An oral solid dosage form, comprising a compressed tablet including an excipient comprising (a) microcrystalline cellulose; and (b) a compressibility augmenting agent which (I) physically restricts the proximity of the interface between adjacent cellulose surfaces (e.g., silicon dioxide); or (ii) inhibits interactions between adjacent cellulose surfaces (e.g., sodium lauryl sulfate); or (iii) accomplishes both (i) and (ii) above; together with an active agent, is disclosed which provides improved disintegration and/or absorptivity to the oral solid dosage form when orally administered to human patients. The excipient comprises agglomerated particles of said microcrystalline cellulose and said compressibility augmenting agent in intimate association with each other.

Claims

1. An oral solid dosage form, comprising

a compressed tablet including an excipient comprising (a) microcrystalline cellulose;

and (b) a compressibility augmenting agent which (i) physically restricts the proximity of the interface between adjacent cellulose surfaces;

or (ii) inhibits interactions between adjacent cellulose surfaces;

or (iii) accomplishes both (i) and (ii) above;

said composition comprising agglomerated particles of said microcrystalline cellulose and said compressibility augmenting agent in intimate association with each other; and

a therapeutically active agent.

2. The composition of claim 1, wherein said compressibility augmenting agent provides a hydrophobic boundary at cellulose surfaces, and improves absorptivity of the therapeutically active agent.

3. The composition of claim 1, wherein said compressibility augmenting agent (i) is a silicon dioxide having an average primary particle size from about 1 nm to about 100 μ

m, and improves disintegration of the dosage form.

4. The composition of claim 1, wherein said compressibility augmenting agent (i) is colloidal silicon dioxide.

5. The composition of claim 1, wherein said compressibility augmenting agent (ii) is a surfactant having an HLB value of at least 10.

6. The composition of claim 1, wherein said compressibility augmenting agent (ii) is a surfactant having an HLB value from about 15 to about 50.

7. The composition of claim 1, wherein said compressibility augmenting agent (ii) is sodium lauryl sulfate.

8. The composition of claim 1, wherein said compressibility augmenting agent (ii) is polysorbate 40.